All About Gout: Arcalyst Meets Phase III Prophylaxis Endpoint...
Following the disclosure of the research data, the share price of Regeneron suffered a decline of 1.46 U.S. dollars. It outlines data from the PREventative Study against URate-lowering drug-Induced Gout Exacerbations (PRE-SURGE) trial.年份: 2010 ...